Vitamins K interact with N-terminus α-synuclein and modulate the protein fibrillization in vitro. Exploring the interaction between quinones and α-synuclein

Neurochemistry International

Volumn 62, Issue 1, 2013, Pages 103-112

  Da Silva, Fernanda Luna ^a   Coelho Cerqueira, Eduardo ^a   De Freitas, Mônica Santos ^a   Gonçalves, Daniela Leão ^b   Costa, Lilian Terezinha ^a,b   Follmer, Cristian ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUTO NACIONAL DE METROLOGIA   (Brazil)

Author keywords

Synuclein; Fibrils; Naphthoquinones; Parkinson's disease; Vitamin K

Indexed keywords

ALPHA SYNUCLEIN; MENADIONE; MENAQUINONE; PHYTOMENADIONE; POLYPHENOL; QUINONE DERIVATIVE;

ARTICLE; CHEMICAL INTERACTION; CONTROLLED STUDY; FIBER; IN VITRO STUDY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; STOICHIOMETRY;

ALPHA-SYNUCLEIN; ANTIFIBRINOLYTIC AGENTS; CELL NUCLEUS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MICROSCOPY, ATOMIC FORCE; NAPHTHOQUINONES; NEUROFIBRILS; QUINONES; VITAMIN K; VITAMIN K 1; VITAMIN K 2; VITAMIN K 3;

EID: 84871721907     PISSN: 01970186     EISSN: 18729754     Source Type: Journal    
DOI: 10.1016/j.neuint.2012.10.001     Document Type: Article

References (64)

1. A.C. Allison The possible role of vitamin K deficiency in the pathogenesis of Alzheimer's disease and in augmenting brain damage associated with cardiovascular disease Med. Hypotheses 57 2001 151 155
2. M.M. Apetri, N.C. Maiti, M.G. Zagorski, P.R. Carey, and V.E. Anderson Secondary structure of alpha-synuclein oligomers: characterization by Raman and atomic force microscopy J. Mol. Biol. 355 2006 63 71
3. M. Baba, S. Nakajo, P.H. Tu, T. Tomita, K. Nakaya, V.M. Lee, J.Q. Trojanowsky, and T. Iwatsubo Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies Am. J. Pathol. 152 1998 879 884
4. T. Bartels, J.G. Choi, and D.J. Selkoe α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation Nature 477 2011 107 110
5. P. Bermejo-Bescós, S. Martín-Aragón, K.L. Jiménez-Aliaga, A. Ortega, M.T. Molina, E. Buxaderas, G. Orellana, and A.G. Csákÿ In vitro antiamyloidogenic properties of 1,4-naphthoquinones Biochem. Biophys. Res. Commun. 400 2010 169 174
6. M. Bisaglia, L. Tosatto, F. Munari, I. Tessari, P.P. de Laureto, S. Mammi, and L. Bubacco Dopamine quinones interact with alpha-synuclein to form unstructured adducts Biochem. Biophys. Res. Commun. 394 2010 424 428
7. C.A. Braga, C. Follmer, F.L. Palhano, E. Khattar, M.S. Freitas, L. Romão, S. Di Giovanni, H.A. Lashuel, J.L. Silva, and D. Foguel The anti-Parkinsonian drug selegiline delays the nucleation phase of α-synuclein aggregation leading to the formation of nontoxic species J. Mol. Biol. 405 2011 254 273
8. R.S. Burns, C.C. Chiueh, S.P. Markey, M.H. Ebert, D.M. Jacobowitz, and I.J. Kopin A primate model of parkinsonism-selective destruction of dopaminergic-neurons in the pars compacta of the substantia nigra by n-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Proc. Natl. Acad. Sci. USA 80 1983 4546 4550
9. R. Cappai, S.L. Leck, D.J. Tew, N.A. Williamson, D.P. Smith, D. Galatis, R.A. Sharples, C.C. Curtain, F.E. Ali, R.A. Cherny, J.G. Culvenor, S.P. Bottomley, C.L. Masters, K.J. Barnham, and A.F. Hill Dopamine promotes alpha-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway FASEB J. 19 2005 1377 1379
10. I. Carrié, J. Portoukalian, R. Vicaretti, J. Rochford, S. Potvin, and G. Ferland Menaquinone-4 concentration is correlated with sphingolipid concentrations in rat brain J. Nutr. 134 2004 167 172
11. K. Castagnoli, J.B. Petzer, S.J. Steyn, C.J. van der Schyf, and N. Castagnoli Jr. Inhibition of human MAO-A and MAO-B by a compound isolated from flue-cured tobacco leaves and its neuroprotective properties in the MPTP mouse model of neurodegeneration Inflammopharmacology 11 2003 183 188
12. B. Caughey, and P.T. Lansbury Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders Annu. Rev. Neurosci. 26 2003 267 298
13. S. Chandra, X. Chen, J. Rizo, R. Jahn, and T.C. Südhof A broken alpha-helix in folded alpha-synuclein J. Biol. Chem. 278 2003 15313 15318
14. E. Coelho-Cerqueira, P.A. Netz, C. Diniz, V. Petry do Canto, and C. Follmer Molecular insights into human monoamine oxidase (MAO) inhibition by 1,4-naphthoquinone: evidences for menadione (vitamin K3) acting as a competitive and reversible inhibitor of MAO Bioorg. Med. Chem. 19 2011 7416 7424
15. K.A. Conway, J.D. Harper, and P.T. Lansbury Jr. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease Nat. Med. 4 1998 1318 1320
16. K.A. Conway, J.D. Harper, and P.T. Lansbury Jr. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid Biochemistry 39 2000 2552 2563
17. K.A. Conway, J.C. Rochet, R.M. Bieganski, and P.T. Lansbury Jr. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct Science 294 2001 1346 1349
18. S. Di Giovanni, S. Eleuteri, K.E. Paleologou, G. Yin, M. Zweckstetter, P.A. Carrupt, and H.A. Lashuel Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of alpha-synuclein and beta-amyloid and protect against amyloid-induced toxicity J. Biol. Chem. 285 2010 14941 14954
19. D. Eliezer, E. Kutluay, R. Bussell Jr., and G. Browne Conformational properties of alpha-synuclein in its free and lipid-associated states J. Mol. Biol. 307 2001 1061 1073
20. B. Fauvet, M.K. Mbefo, M.B. Fares, C. Desobry, S. Michael, M.T. Ardah, E. Tsika, P. Coune, M. Prudent, N. Lion, D. Eliezer, D.J. Moore, B. Schneider, P. Aebischer, O.M. El-Agnaf, E. Masliah, and H.A. Lashuel α-synuclein in the central nervous system and from erythrocytes, mammalian cells and E. coli exists predominantly as a disordered monomer J. Biol. Chem. 287 2012 15345 15364
21. G. Ferland, D.L. MacDonald, and J.A. Sadowski Development of a diet low in vitamin K-1 (phylloquinone) J. Am. Diet Assoc. 92 1992 593 597
22. C. Follmer, L. Romão, C.M. Einsiedler, T.C.R. Porto, F. Lara, M. Monçores, G. Weissmüller, H.A. Lashuel, P. Lansbury, V. Moura-Neto, J.L. Silva, and D. Foguel Dopamine affects the stability, hydration and packing of protofibrils and fibrils of wild-type and variants of α-synuclein Biochemistry 46 2007 472 482
23. M. Goedert Alpha-synuclein and neurodegenerative diseases Nat. Rev. Neurosci. 2 2001 492 501
24. E.A. Greenbaum, C.L. Graves, A.J. Mishizen-Eberz, M.A. Lupoli, D.R. Lynch, S.W. Englander, P.H. Axelsen, and B.I. Giasson The E46K mutation in alpha-synuclein increases amyloid fibril formation J. Biol. Chem. 280 2005 7800 7807
25. M.K. Hadden, S.A. Hill, J. Davenport, R.L. Matts, and B.S. Blagg Synthesis and evaluation of Hsp90 inhibitors that contain the 1,4-naphthoquinone scaffold Bioorg. Med. Chem. 17 2009 634 640
26. R. Harada, N. Kobayashi, J. Kim, C. Nakamura, S.W. Han, K. Ikebukuro, and K. Sode The effect of amino acid substitution in the imperfect repeat sequences of alpha-synuclein on fibrillation Biochim. Biophys. Acta 1792 2009 998 1003
27. M.M. Hoehn, and M.D. Yahr Parkinsonism-onset progression and mortality Neurology 17 1967 427 442
28. M.J. Hope, M.B. Bally, G. Webb, and P.R. Cullis Production of large unilamellar vesicles by a rapid extrusion procedure. Characterization of size distribution, trapped volume and ability to maintain a membrane potential Biochim. Biophys. Acta 812 1985 55 65
29. S.A. Hudson, H. Ecroyd, T.W. Kee, and J.A. Carver The thioflavin T fluorescence assay for amyloid fibril detection can be biased by the presence of exogenous compounds FEBS J. 276 2009 5960 5972
30. A.J. Hughes, S.E. Daniel, L. Kilford, and A.J. Lees Accuracy of clinical-diagnosis of idiopathic Parkinson's disease-a clinicopathological study of 100 cases J. Neurol. Neurosurg. Psychiatry 55 1992 181 184
31. P. Jenner Oxidative stress in Parkinson's disease Ann. Neurol. 53 2003 26 38
32. T. Kasahara, and T. Kato Nutritional biochemistry: a new redoxcofactor vitamin for mammals Nature 422 2003 832
33. D.A. Kendall, and R.C. MacDonald A fluorescence assay to monitor vesicle fusion and lysis J. Biol. Chem. 257 1982 13892 13895
34. J. Killgore, C. Smidt, L. Duich, N. Romero-Chapman, D. Tinker, K. Reiser, M. Melko, D. Hyde, and R.B. Rucker Nutritional importance of pyrroloquinoline quinone Science 245 1989 850 852
35. J. Kim, R. Harada, M. Kobayashi, N. Kobayashi, and K. Sode The inhibitory effect of pyrroloquinoline quinone on the amyloid formation and cytotoxicity of truncated alpha-synuclein Mol. Neurodegener. 5 2010 20
36. J. Kim, M. Kobayashi, M. Fukuda, D. Ogasawara, N. Kobayashi, S. Han, C. Nakamura, M. Inada, C. Miyaura, K. Ikebukuro, and K. Sode Pyrroloquinoline quinone inhibits the fibrillation of amyloid proteins Prion 4 2010 26 31
37. M. Kobayashi, J. Kim, N. Kobayashi, S. Han, C. Nakamura, K. Ikebukuro, and K. Sode Pyrroloquinoline quinone (PQQ) prevents fibril formation of alpha-synuclein Biochem. Biophys. Res. Commun. 349 2006 1139 1144
38. N. Kobayashi, J. Kim, K. Ikebukuro, and K. Sode The inhibition of amyloid fibrillation using the proteolytic products of PQQ-modified α-synuclein Open Biotechnol. J. 3 2009 40 45
39. H.A. Lashuel, D. Hartley, B.M. Petre, T. Walz, and P.T. Lansbury Jr. Neurodegenerative disease: amyloid pores from pathogenic mutations Nature 418 2002 291
40. A.J. Lees, J. Hardy, and T. Revesz Parkinson's disease Lancet 373 2009 2055 2066
41. S.L. Leong, R. Cappai, K.J. Barnham, and C.L. Pham Modulation of alpha-synuclein aggregation by dopamine: a review Neurochem. Res. 34 2009 1838 1846
42. S.L. Leong, C.L. Pham, D. Galatis, M.T. Fodero-Tavoletti, K. Perez, A.F. Hill, C.L. Masters, F.E. Ali, K.J. Barnham, and R. Cappai Formation of dopamine-mediated alpha-synuclein-soluble oligomers requires methionine oxidation Free Radic. Biol. Med. 46 2009 1328 1337
43. J. Li, M. Zhu, A.B. Manning-Bog, D.A. Di Monte, and A.L. Fink Dopamine and L-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease FASEB J. 18 2004 962 964
44. H.T. Li, D.H. Lin, X.Y. Luo, F. Zhang, L.N. Ji, H.N. Du, G.Q. Song, J. Hu, J.W. Zhou, and H.Y. Hu Inhibition of alpha-synuclein fibrillization by dopamine analogs via reaction with the amino groups of alpha-synuclein. Implication for dopaminergic neurodegeneration FEBS J. 272 2005 3661 3672
45. C.F. Lippa, H. Fujiwara, D.M. Mann, B. Giasson, M. Baba, M.L. Schmidt, L.E. Nee, B. ÓConnel, D.A. Pollen, P. St George-Hyslop, B. Ghetti, D. Nochlin, T.D. Bird, N.J. Cairns, V.M. Lee, T. Twatsubo, and J.Q. Trojanowski Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimeŕ's disease patients with mutations in preselin and amyloid precursor protein genes Am. J. Pathol. 153 1998 1365 1370
46. S.M. Lippa, C.F. Lippa, and H. Mori α-Synuclein aggregation in pathological aging and Alzheimer's disease: the impact of β-amyloid plaque level Am. J. Alzheimers Dis. Other Demen. 20 2005 315 318
47. G. Muntané, I. Ferrer, and M. Martinez-Vicente α-synuclein phosphorylation and truncation are normal events in the adult human brain Neurosci. 200 2012 106 119
48. E.H. Norris, B.I. Giasson, R. Hodara, S. Xu, J.Q. Trojanowski, H. Ischiropoulos, and V.M. Lee Reversible inhibition of alpha-synuclein fibrillization by dopaminochrome-mediated conformational alterations J. Biol. Chem. 280 2005 21212 21219
49. K. Ono, and M. Yamada Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro J. Neurochem. 97 2006 105 115
50. K. Ono, M. Hirohata, and M. Yamada Anti-fibrillogenic and fibril-destabilizing activities of anti-Parkinsonian agents for alpha-synuclein fibrils in vitro J. Neurosci. Res. 85 2007 1547 1557
51. K. Ono, and M. Yamada Vitamin A potently destabilizes preformed alpha-synuclein fibrils in vitro: implications for Lewy body diseases Neurobiol. Dis. 25 2007 446 454
52. N. Pandey, R.E. Schmidt, and J.E. Galvin The α-synuclein mutation E46K promotes aggregation in cultured cells Exp. Neurol. 197 2006 515 520
53. C.L. Pham, S.L. Leong, F.E. Ali, V.B. Kenche, A.F. Hill, S.L. Gras, K.J. Barnham, and R. Cappai Dopamine and the dopamine oxidation product 5,6-dihydroxylindole promote distinct on-pathway and off-pathway aggregation of alpha-synuclein in a pH-dependent manner J. Mol. Biol. 387 2009 771 785
54. M.H. Polymeropoulos, C. Lavedan, E. Leroy, S.E. Ide, A. Dehejia, A. Dutra, B. Pike, H. Root, J. Rubenstein, R. Boyer, E.S. Stenroos, S. Chandrasekharappa, A. Athanassiadou, T. Papapetropoulos, W.G. Johnson, A.M. Lazzarini, R.C. Duvoisin, G. DiIorio, L.I. Golbe, and R.L. Nussbaum Mutation in the alpha-synuclein gene identified in families with Parkinson's disease Science 276 1997 2045 2047
55. M. Piotto, V. Saudek, and V. Sklenar Gradient-tailored excitation for single-quantum NMR spectroscopy of aqueous solutions J. Biomol. NMR 2 1992 661 665
56. N. Presse, B. Shatenstein, M.J. Kergoat, and G. Ferland Low vitamin K intakes in community-dwelling elders at an early stage of Alzheimer's disease J. Am. Diet Assoc. 108 2008 2095 2099
57. J.N. Rao, Y.E. Kim, L.S. Park, and T.S. Ulmer Effect of pseudorepeat rearrangement on alpha-synuclein misfolding, vesicle binding, and micelle binding J. Mol. Biol. 390 2009 516 529
58. M.G. Spillantini, M.L. Schmidt, V.M. Lee, J.Q. Trojanowski, R. Jakes, and M. Goedert Alpha-synuclein in Lewy bodies Nature 388 1997 839 840
59. W.F. Vranken, W. Boucher, T.J. Stevens, R.H. Fogh, A. Pajon, P. Llinas, E.L. Ulrich, J.L. Markley, J. Ionides, and E.D. Laue The CCPN data model for NMR spectroscopy: development of a softwarepipeline Proteins 59 2005 687 696
60. M.J. Volles, S.J. Lee, J.C. Rochet, M.D. Shtilerman, T.T. Ding, J.C. Kessler, and P.T. Lansbury Jr. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease Biochemistry 40 2001 7812 7819
61. K. Wakabayashi, M. Yoshimoto, S. Tsuji, and H. Takahashi Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy Neurosci. Lett. 249 1998 180 182
62. T. Yagami, K. Ueda, K. Asakura, T. Sakaeda, H. Nakazato, T. Kuroda, S. Hata, G. Sakaguchi, N. Itoh, T. Nakano, Y. Kambayashi, and H. Tsuzuki Gas6 rescues cortical neurons from amyloid beta protein-induced apoptosis Neuropharmacology 43 2002 1289 1296
63. M.B. Youdim, and Y.S. Bakhle Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness Br. J. Pharmacol. 147 2006 287 296
64. M. Zhu, S. Rajamani, J. Kaylor, S. Han, F. Zhou, and A.L. Fink The flavonoid baicalein inhibits fibrillation of alpha-synuclein and disaggregates existing fibrils J. Biol. Chem. 279 2004 26846 26857